 On August 16, 2012, the Federal Circuit reaffirmed Myriad's right to patent the genes although they denied rights to patent comparisons of DNA sequences.On November 30, 2012, the Supreme Court agreed to hear a second challenge to the two gene patents held by Myriad.Oral argument took place on April 15, 2013.